Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Enochian Biosciences Inc

Start price
Target price
Perf. (%)
€4.36
04.10.23
-
04.10.24
-24.77%
11.12.23

Probably not worthwhile Investment
buy
Capital Southwest Corp

Start price
Target price
Perf. (%)
€20.72
03.10.23
-
03.10.24
15.73%
31.01.24

buy
Adocia

Start price
Target price
Perf. (%)
€8.54
02.10.23
-
02.10.24
-3.28%
10.12.23

Could be worthwhile Investment >10% per year
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.94
02.10.23
-
02.10.24
-13.79%
15.10.23

Could be very worthwhile Investment >20% year
buy
Sportsmans Wareh.ho.

Start price
Target price
Perf. (%)
€4.28
01.10.23
€4.50
30.09.25
11.68%
16.10.23

Could be very worthwhile Investment >20% year
buy
Aldeyra Therapeutics Inc.

Start price
Target price
Perf. (%)
€6.42
01.10.23
€10.00
30.11.25
-73.55%
16.10.23

Could be very worthwhile Investment >20% year
buy
Immunic Inc.

Start price
Target price
Perf. (%)
€1.37
01.10.23
€3.00
28.02.26
-13.40%
18.02.24

Could be very worthwhile Investment >20% year
buy
Akero Therapeutics Inc

Start price
Target price
Perf. (%)
€47.80
01.10.23
€65.00
30.06.26
-71.13%
13.10.23

Could be very worthwhile Investment >20% year
Mithra Pharmaceuticals S.A.

Start price
Target price
Perf. (%)
€1.40
30.09.23
€1.00
30.09.24
-21.00%
14.10.23

Probably not worthwhile Investment
Bad rating
Little Investments for future growth
Risky balance sheet
Capricor Therapeutics Inc

Start price
Target price
Perf. (%)
€3.32
30.09.23
€1.00
30.09.24
-17.17%
14.10.23

EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
buy
Deutsche Rohstoff AG

Start price
Target price
Perf. (%)
€31.20
27.09.23
€32.00
27.09.24
7.69%
18.10.23

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Rising EBIT margin expected
Fair valuation
buy
MicroVision Inc

Start price
Target price
Perf. (%)
€2.11
27.09.23
€4.00
27.09.24
5.76%
23.11.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
ShiftPixy Inc.

Start price
Target price
Perf. (%)
€0.89
27.09.23
-
27.09.24
-13.68%
30.09.23

Could be very worthwhile Investment >20% year
buy
ShiftPixy Inc.

Start price
Target price
Perf. (%)
€1.07
27.09.23
-
27.09.24
-28.63%
30.09.23

Could be worthwhile Investment >10% per year
buy
Intercept Pharmaceuticals

Start price
Target price
Perf. (%)
€17.61
26.09.23
-
26.09.24
-1.48%
30.09.23

Risky Investment
buy
Super Micro Computer

Start price
Target price
Perf. (%)
€236.20
26.09.23
-
26.09.24
259.70%
15.02.24

buy
Vericel Corp.

Start price
Target price
Perf. (%)
€31.80
26.09.23
-
26.09.24
27.04%
31.01.24

buy
DBAG Deutsche Beteiligungs AG

Start price
Target price
Perf. (%)
€31.10
26.09.23
-
26.09.24
-9.49%
31.01.24

buy
Sientra Inc.

Start price
Target price
Perf. (%)
€2.52
25.09.23
€5.20
25.09.24
-23.41%
11.10.23

Could be very worthwhile Investment >20% year
buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.02
21.09.23
-
21.09.24
-7.27%
01.10.23

Could be very worthwhile Investment >20% year
buy
Paradox Interactive publ AB

Start price
Target price
Perf. (%)
€20.58
21.09.23
-
21.09.24
-19.73%
18.03.24

buy
Limelight Networks Inc.

Start price
Target price
Perf. (%)
€0.88
21.09.23
-
21.09.24
-78.43%
15.02.24

buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.25
20.09.23
-
20.09.24
-24.48%
02.10.23

Could be worthwhile Investment >10% per year
buy
Vita 34 AG

Start price
Target price
Perf. (%)
€4.76
19.09.23
€6.00
19.09.24
-1.68%
30.09.23

Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
MicroVision Inc

Start price
Target price
Perf. (%)
€2.02
19.09.23
€4.00
19.09.24
4.43%
27.09.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected